CEO Files Intent to Sell Over $5 Million in Company Stock
Summary
Protagonist Therapeutics' CEO filed a Form 144 to sell $5.39 million in stock, continuing a pattern of insider sales.
Key Events
-
CEO Files Intent to Sell Shares
Dinesh Patel, CEO of Protagonist Therapeutics, filed a Form 144 to sell 54,700 shares of common stock.
-
Significant Proposed Transaction Value
The proposed sale is valued at approximately $5.39 million.
-
Follows Recent Insider Sales
This intent to sell follows previous sales by the CEO totaling $4.06 million in the past three months, contributing to a net insider distribution of nearly $13 million over 90 days.
-
Part of Ongoing Insider Distribution
This filing is part of an ongoing pattern of insider sales, with 10 similar filings from various insiders in the last 90 days.
Analysis
Protagonist Therapeutics' CEO, Dinesh Patel, has filed a Form 144 indicating an intent to sell 54,700 shares of common stock, valued at approximately $5.39 million. This proposed sale follows previous sales by the CEO totaling over $4 million in the past three months, contributing to a broader pattern of insider distribution. While the percentage of market cap is small, the absolute dollar value and the CEO's role make this a notable event, signaling a continued reduction in executive holdings.
At the time of this filing, PTGX was trading at $100.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $39.60 to $105.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.